权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel vaccines for otitis media

中耳炎新型疫苗

基本信息

批准号：
7933803
负责人：
Elaine I Tuomanen
金额：
$ 40.08万
依托单位：
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-17 至 2012-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7933803
关键词：
Acute Address Adverse effects Animal Model Animals Antibiotic Therapy Antibiotics Antibodies Antibody Formation Applications Grants Area Attention Attenuated Attenuated Live Virus Vaccine B-Lymphocytes CD4 Positive T Lymphocytes Cells Child Childhood Clinic Clinical Clinical Data Clinical Research Conjugate Vaccines Data Development Disease Drug resistance Economic Burden Effectiveness Ferrets Funding Grant Helper-Inducer T-Lymphocyte Immune Immune response Immunobiology Immunoglobulin Class Switching Immunology Infection Infection prevention Knowledge Life Link Mediating Medical Membrane Proteins Methods Modeling Mucosal Immune Responses Mucosal Immunity Mus Otitis Media Patient observation Physicians Pneumococcal Infections Pneumococcal vaccine Pneumonia Population Prevention Prevnar Recommendation Recovery Relative (related person)Resistance Risk Factors Running Serotyping Streptococcus pneumoniae T cell response Testing Vaccinated Vaccination Vaccines Visit Work capsule cost meetings novel novel vaccines pre-clinical prevent protective efficacy public health relevance response stem vaccination strategy vaccine candidate

项目摘要

DESCRIPTION (provided by applicant): This proposal meets the requirements of two major Challenge Areas within Clinical Research, "Prevention of otitis media" (04-DC101), and "Develop novel methods and address key questions in mucosal immunology" (04-AI-101). Otitis media caused by Streptococcus pneumoniae represents a significant medical burden in children. While the advent of the pneumococcal polyvalent conjugate vaccine Prevnar has decreased the burden of pneumococcal disease overall, the suboptimal mucosal immune response has proved problematic in eliciting effective protection. Even with vaccination, acute otitis media is the leading cause of pediatric physician visits and is responsible for a majority of the antibiotics prescribed to young children. This underscores the importance of development of new vaccination strategies and a greater understanding of host mucosal immunity. To this end, intranasal vaccination has recently gained considerable attention as an alternative strategy due to potential effectiveness at inducing a robust mucosal immune response. We propose to evaluate the immune responses and protective efficacy of two novel live, attenuated pneumococcal vaccines against otitis media using newly described, robust animal models. These data are expected to expand our knowledge of mucosal immunity to otitis media and provide pre-clinical data useful for advancing novel vaccines to the clinic. PUBLIC HEALTH RELEVANCE: Otitis media caused by Streptococcus pneumoniae represents a significant medical burden in children. While the advent of the pneumococcal polyvalent conjugate vaccine Prevnar has decreased the burden of pneumococcal disease overall, the suboptimal mucosal immune response has proved problematic in eliciting effective protection. Even with vaccination, acute otitis media is the leading cause of pediatric physician visits and is responsible for a majority of the antibiotics prescribed to young children. This underscores the importance of development of new vaccination strategies and a greater understanding of host mucosal immunity. To this end, intranasal vaccination has recently gained considerable attention as an alternative strategy due to potential effectiveness at inducing a robust mucosal immune response. We propose to evaluate the immune responses and protective efficacy of two novel live, attenuated pneumococcal vaccines against otitis media using newly described, robust animal models. These data are expected to expand our knowledge of mucosal immunity to otitis media and provide pre-clinical data useful for advancing novel vaccines to the clinic.

描述（由申请人提供）：本提案符合临床研究中两个主要挑战领域的要求，“预防中耳炎”（04-DC101）和“开发新方法并解决粘膜免疫学中的关键问题”（04-AI-101）。